logo
logo
HomeAbout UsPlatformInsights

Clinical Trial Insights

AllClinical TrialRegulatoryMerger & AcquisitionsBlogs
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III Hypertension TrialClinical Trial Updates

Baxdrostat Shows Significant Blood Pressure Reduction in Phase III Hypertension Trial

Positive results from the BaxHTN Phase III trial demonstrated that baxdrostat, a highly selective aldosterone synthase inhibitor, significantly reduce...

4TEEN4 Announces Promising First-in-Human Data for Procizumab in Cardiogenic ShockClinical Trial Updates

4TEEN4 Announces Promising First-in-Human Data for Procizumab in Cardiogenic Shock

4TEEN4 Pharmaceuticals announced the publication of data in the European Journal of Heart Failure demonstrating the efficacy and safety of procizumab,...

Bicara Therapeutics Announces Positive Interim Data for Ficerafusp Alfa in Head and Neck CancerClinical Trial Updates

Bicara Therapeutics Announces Positive Interim Data for Ficerafusp Alfa in Head and Neck Cancer

Bicara Therapeutics announced updated interim data from a Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab for first-lin...

Alto Neuroscience Validates EEG Biomarker for Schizophrenia, Strengthening Phase 2 Trial of ALTO-101Clinical Trial Updates

Alto Neuroscience Validates EEG Biomarker for Schizophrenia, Strengthening Phase 2 Trial of ALTO-101

Alto Neuroscience announced positive results from an independent, prospective replication study validating theta-band inter-trial coherence (ITC) as a...

BioInvent Announces Positive Phase 1 Data for BI-1206 in Combination with Pembrolizumab in Solid TumorsClinical Trial Updates

BioInvent Announces Positive Phase 1 Data for BI-1206 in Combination with Pembrolizumab in Solid Tumors

BioInvent International AB announced positive Phase 1 data for its drug candidate BI-1206, used in combination with Merck's KEYTRUDA (pembrolizumab), ...

Actuate Therapeutics Announces Positive Phase 2 Elraglusib Data in Metastatic Pancreatic CancerClinical Trial Updates

Actuate Therapeutics Announces Positive Phase 2 Elraglusib Data in Metastatic Pancreatic Cancer

Actuate Therapeutics announced positive topline Phase 2 data for elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metasta...

Boehringer Ingelheim to Present Early Clinical Data on SIRPα Inhibitors at ASCO 2025Clinical Trial Updates

Boehringer Ingelheim to Present Early Clinical Data on SIRPα Inhibitors at ASCO 2025

Boehringer Ingelheim will present data from two early-stage clinical trials investigating their SIRPα inhibitors, BI 765063 and BI 770371, at the 2025...

Anaptys Announces Positive Phase 2b Results for Rosnilimab in Rheumatoid ArthritisClinical Trial Updates

Anaptys Announces Positive Phase 2b Results for Rosnilimab in Rheumatoid Arthritis

AnaptysBio announced positive late-breaking data from its Phase 2b trial of rosnilimab in rheumatoid arthritis (RA). The study demonstrated deepening ...

Boehringer and Click Therapeutics present positive Phase III data for CT-155 in SchizophreniaClinical Trial Updates

Boehringer and Click Therapeutics present positive Phase III data for CT-155 in Schizophrenia

Boehringer Ingelheim and Click Therapeutics announced positive results from the Phase III CONVOKE study of CT-155, an investigational prescription dig...

AbCellera Announces Positive Preclinical Data for ABCL575, an Anti-OX40L Antibody for Atopic DermatitisClinical Trial Updates

AbCellera Announces Positive Preclinical Data for ABCL575, an Anti-OX40L Antibody for Atopic Dermatitis

AbCellera presented preclinical data on ABCL575, a half-life extended anti-OX40L monoclonal antibody for moderate-to-severe atopic dermatitis. The da...

Bolt Biotherapeutics Updates on BDC-4182 and Extends Cash Runway into 2027Clinical Trial Updates

Bolt Biotherapeutics Updates on BDC-4182 and Extends Cash Runway into 2027

Bolt Biotherapeutics announced an update on its Phase 1 dose escalation study of BDC-4182, an ISAC targeting claudin 18.2 for cancer treatment. Initia...

Apnimed Presents Phase 3 Data for AD109 in Obstructive Sleep Apnea at CHEST 2025Clinical Trial Updates

Apnimed Presents Phase 3 Data for AD109 in Obstructive Sleep Apnea at CHEST 2025

Apnimed announced additional data from its Phase 3 SynAIRgy and LunAIRo trials evaluating AD109 (aroxybutynin 2.5 mg/atomoxetine 75 mg) for obstructiv...

Breath Diagnostics' OneBreath™ Technology Predicts Pneumonia Onset Through Exhaled Breath AnalysisClinical Trial Updates

Breath Diagnostics' OneBreath™ Technology Predicts Pneumonia Onset Through Exhaled Breath Analysis

Breath Diagnostics announced results from a peer-reviewed clinical study published in The Journal of Thoracic and Cardiovascular Surgery, demonstratin...

Adagene Announces Positive Updated Data for Muzastotug (ADG126) in Combination with Pembrolizumab for Colorectal Cancer at ASCOClinical Trial Updates

Adagene Announces Positive Updated Data for Muzastotug (ADG126) in Combination with Pembrolizumab for Colorectal Cancer at ASCO

Adagene announced updated Phase 1b/2 data for its anti-CTLA-4 antibody, Muzastotug (ADG126), in combination with pembrolizumab, in patients with micro...

BriaCell's Phase 2 Trial Shows Promising Survival Rates in Metastatic Breast CancerClinical Trial Updates

BriaCell's Phase 2 Trial Shows Promising Survival Rates in Metastatic Breast Cancer

BriaCell Therapeutics Corp. announced updated survival data from its Phase 2 clinical study of Bria-IMT in patients with metastatic breast cancer (MBC...

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Pain TreatmentClinical Trial Updates

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Pain Treatment

Artelo Biosciences announced positive results from its first-in-human Phase 1 study of ART26.12, a novel, orally administered FABP5 inhibitor for pers...

Cantargia's CAN10 Shows Promise in Inhibiting Vascular InflammationClinical Trial Updates

Cantargia's CAN10 Shows Promise in Inhibiting Vascular Inflammation

Cantargia AB announced promising preclinical results for CAN10, an antibody targeting IL1RAP, in vascular inflammation models. The study, published i...

CASI Pharmaceuticals Announces Dose Escalation in Phase 1 CID-103 ITP StudyClinical Trial Updates

CASI Pharmaceuticals Announces Dose Escalation in Phase 1 CID-103 ITP Study

CASI Pharmaceuticals announced that the Safety Monitoring Committee (SMC) recommended dose escalation of CID-103, an anti-CD38 monoclonal antibody, to...

Ascletis Initiates Phase IIa Trial of Oral GLP-1R Agonist ASC30 for ObesityClinical Trial Updates

Ascletis Initiates Phase IIa Trial of Oral GLP-1R Agonist ASC30 for Obesity

Ascletis Pharma announced the first participants have been dosed in a Phase IIa clinical trial (NCT07002905) evaluating ASC30, a novel small molecule ...

Cassava Sciences Reports Positive Preclinical Study of Simufilam for TSC-Related EpilepsyClinical Trial Updates

Cassava Sciences Reports Positive Preclinical Study of Simufilam for TSC-Related Epilepsy

Cassava Sciences announced positive preclinical results for simufilam in a mouse model of tuberous sclerosis complex (TSC)-related epilepsy. The stud...

Airiver Medical Receives FDA IDE Approval for Pivotal Clinical Study of Airiver Pulmonary Drug Coated BalloonClinical Trial Updates

Airiver Medical Receives FDA IDE Approval for Pivotal Clinical Study of Airiver Pulmonary Drug Coated Balloon

Airiver Medical announced that it has received Investigational Device Exemption (IDE) approval from the FDA to conduct a pivotal clinical trial of its...

CeleCor Therapeutics Announces Positive Phase 3 Results for Disaggpro in Heart Attack PatientsClinical Trial Updates

CeleCor Therapeutics Announces Positive Phase 3 Results for Disaggpro in Heart Attack Patients

CeleCor Therapeutics announced positive topline results from its Phase 3 CeleBrate trial evaluating Disaggpro™ (zalunfiban) for heart attack treatment...

AskBio Announces Positive 12-Month Data from Phase 1 Trial of AB-1002 Gene Therapy for Congestive Heart Failure in Nature MedicineClinical Trial Updates

AskBio Announces Positive 12-Month Data from Phase 1 Trial of AB-1002 Gene Therapy for Congestive Heart Failure in Nature Medicine

AskBio, a subsidiary of Bayer AG, announced the publication of 12-month data from its Phase 1 trial of AB-1002 gene therapy for congestive heart failu...

Cizzle Bio Submits NIH Grant for Lung Cancer Biomarker Blood TestClinical Trial Updates

Cizzle Bio Submits NIH Grant for Lung Cancer Biomarker Blood Test

Cizzle Bio, a biotechnology company, submitted a grant application to the NIH for a two-year study validating its CIZ1B biomarker for early-stage lung...

AbbVie's VERONA Trial for Higher-Risk Myelodysplastic Syndromes Misses Primary EndpointClinical Trial Updates

AbbVie's VERONA Trial for Higher-Risk Myelodysplastic Syndromes Misses Primary Endpoint

AbbVie announced that the Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for newly diagnosed higher-risk myelodysplastic s...

Clene Provides Regulatory Update on CNM-Au8 for ALS and MSClinical Trial Updates

Clene Provides Regulatory Update on CNM-Au8 for ALS and MS

Clene, Inc. announced a positive Type C meeting with the FDA regarding its statistical analysis plan for CNM-Au8 in ALS patients. The FDA provided co...

Aspire Biopharma Announces Positive Final Results for Sublingual Aspirin in Treating Heart AttacksClinical Trial Updates

Aspire Biopharma Announces Positive Final Results for Sublingual Aspirin in Treating Heart Attacks

Aspire Biopharma announced positive final results from a clinical trial evaluating its investigational sublingual aspirin product for suspected acute ...

Compass Pathways Announces Positive Phase 2 Results for COMP360 Psilocybin in PTSDClinical Trial Updates

Compass Pathways Announces Positive Phase 2 Results for COMP360 Psilocybin in PTSD

Compass Pathways announced the publication of positive Phase 2 results for their investigational drug COMP360, a synthetic psilocybin, in treating pos...

Alafair Biosciences Initiates Multi-Center Study on VersaWrap® for Achilles Tendon RepairClinical Trial Updates

Alafair Biosciences Initiates Multi-Center Study on VersaWrap® for Achilles Tendon Repair

Alafair Biosciences announced the enrollment of the first patient in a multi-center study evaluating VersaWrap®, a bioresorbable tendon protector, for...

Coya Therapeutics Announces FDA Acceptance of IND for COYA 302 to Treat ALSClinical Trial Updates

Coya Therapeutics Announces FDA Acceptance of IND for COYA 302 to Treat ALS

Coya Therapeutics announced that the FDA has accepted its Investigational New Drug (IND) application for COYA 302, a biologic combination therapy for ...

Atossa Therapeutics Receives Positive FDA Feedback for (Z)-Endoxifen in Metastatic Breast CancerClinical Trial Updates

Atossa Therapeutics Receives Positive FDA Feedback for (Z)-Endoxifen in Metastatic Breast Cancer

Atossa Therapeutics announced positive feedback from the FDA regarding its proposed dose optimization trial of (Z)-endoxifen for ER+/HER2- metastatic ...

CureGene's CG-0416 Shows Promise as Dual-Action Therapy for Obesity and MASHClinical Trial Updates

CureGene's CG-0416 Shows Promise as Dual-Action Therapy for Obesity and MASH

CureGene Pharmaceuticals announced preclinical data for its investigational drug, CG-0416, a liver-targeted thyroid hormone receptor beta (THR-β) prod...

AL-S Pharma Announces Positive Phase 2 Results for AP-101 in ALS TreatmentClinical Trial Updates

AL-S Pharma Announces Positive Phase 2 Results for AP-101 in ALS Treatment

AL-S Pharma reported positive topline results from its Phase 2 clinical trial of AP-101, a first-in-class monoclonal antibody targeting misfolded SOD1...

Autobahn Therapeutics Presents Positive Phase 1 Results for ABX-002 at ASCP Annual MeetingClinical Trial Updates

Autobahn Therapeutics Presents Positive Phase 1 Results for ABX-002 at ASCP Annual Meeting

Autobahn Therapeutics announced positive Phase 1 clinical trial results for ABX-002, a novel thyroid hormone beta receptor (TRβ) selective agonist, at...

4B Technologies Announces Positive Phase 1 Results for Novel Non-Opioid Chronic Pain TherapyClinical Trial Updates

4B Technologies Announces Positive Phase 1 Results for Novel Non-Opioid Chronic Pain Therapy

4B Technologies announced positive topline results from a Phase 1 study of 4B03-04, a humanized monoclonal antibody for chronic pain. The trial demon...

AB Science Announces Initial Phase 1 Data for AB8939 and Venetoclax Combination in Refractory or Relapsed Acute Myeloid LeukemiaClinical Trial Updates

AB Science Announces Initial Phase 1 Data for AB8939 and Venetoclax Combination in Refractory or Relapsed Acute Myeloid Leukemia

AB Science SA announced initial Phase 1 data for the combination of AB8939 with venetoclax for treating refractory or relapsed acute myeloid leukemia ...

AbbVie Announces Positive Phase 3 Results for Upadacitinib (RINVOQ®) in VitiligoClinical Trial Updates

AbbVie Announces Positive Phase 3 Results for Upadacitinib (RINVOQ®) in Vitiligo

AbbVie announced positive topline results from two replicate Phase 3 studies evaluating upadacitinib (RINVOQ®) in adult and adolescent patients with n...

Aicuris' Pritelivir Meets Primary Endpoint in Phase 3 Trial for Refractory Herpes Simplex Virus in Immunocompromised PatientsClinical Trial Updates

Aicuris' Pritelivir Meets Primary Endpoint in Phase 3 Trial for Refractory Herpes Simplex Virus in Immunocompromised Patients

Aicuris Anti-infective Cures AG announced positive results from its Phase 3 trial (PRIOH-1) of pritelivir for treating refractory Herpes Simplex Virus...

Ascentage Pharma's Lisaftoclax Shows Promise in Venetoclax-Refractory Patients; ASCO 2025 PresentationClinical Trial Updates

Ascentage Pharma's Lisaftoclax Shows Promise in Venetoclax-Refractory Patients; ASCO 2025 Presentation

Ascentage Pharma announced positive clinical data for lisaftoclax, a Bcl-2 inhibitor, and alrizomadlin, an MDM2-p53 inhibitor. Data from a Phase 1b/2...

Candel Therapeutics to Present CAN-2409 Data at SITC 2025Clinical Trial Updates

Candel Therapeutics to Present CAN-2409 Data at SITC 2025

Candel Therapeutics will present data from its enLIGHTEN™ Discovery Platform and CAN-2409 program in non-small cell lung cancer (NSCLC) at the SITC 20...

← PrevPage 2 of 8Next →

Get a Demo of the Enterprise AI & Knowledge Platform

Private by design. Speaks your language. Proven at scale

Book a Demo